Editorial Comments to “Prognostic Significance of Hypoalbuminemia in Maintenance Avelumab Therapy After First‐Line Chemotherapy for Metastatic Urothelial Carcinoma: A Multicenter Real‐World Study ( YUSHIMA Study)”

Maintenance avelumab therapy has become a standard of care for patients with locally advanced or metastatic urothelial carcinoma (mUC) who achieve disease control after first-line platinum-based chemotherapy [1]. While the pivotal JAVELIN Bladder 100 trial established its survival benefit [2], identifying patients most likely to benefit from this strategy remains a key clinical challenge. In this context, the YUSHIMA study by Muta et al. provides valuable real-world evidence highlighting the prognostic significance of hypoalbuminemia in patients receiving maintenance avelumab therapy [3]. The authors demonstrated that baseline hypoalbuminemia was independently associated with shorter progression-free survival and overall survival. Importantly, this finding is consistent with accumulating evidence across malignancies indicating that serum albumin reflects not only nutritional status but also systemic inflammation and tumor burden, all of which may influence the efficacy of immune checkpoint inhibitors [4]. In patients treated with avelumab, no robust biomarkers are currently available in routine clinical practice; therefore, simple and readily available markers are particularly attractive for decision-making. One noteworthy aspect of this study is the assessment of changes in serum albumin levels during first-line chemotherapy. The finding that albumin levels increased in some patients while decreasing in others suggests that albumin reflects not only baseline host condition but also the patient's physiological reserve during treatment, including the capacity to tolerate chemotherapy-related anorexia, inflammation, and metabolic stress. These observations raise the possibility that longitudinal monitoring of albumin may provide additional prognostic information beyond a single baseline measurement. Several limitations should be acknowledged when interpreting these results. First, the retrospective nature of the study introduces the potential for selection bias and unmeasured confounding. In addition, the relatively small sample size may limit statistical power, particularly for detecting the impact of clinical variables other than albumin. The heterogeneity in subsequent therapies across institutions further complicates the interpretation of survival outcomes. These factors may collectively limit the generalizability of the findings. Nevertheless, real-world data reported by Muta et al. provide valuable insight into routine clinical practice and remain informative. In summary, the YUSHIMA study underscores the prognostic value of serum albumin in patients with mUC treated with maintenance avelumab therapy. Hypoalbuminemia may help identify patients at higher risk of poor outcome. Future prospective studies are needed to clarify whether interventions targeting nutritional and inflammatory status can improve outcomes in patients receiving maintenance avelumab therapy. N.F.: conceptualization, project administration, writing original draft, writing review and editing. The author declares no conflicts of interest. Data sharing not applicable to this article as no datasets were generated or analysed during the current study.